



## Cardiovascular Neuromodulatory Therapy

Guest Editors:

**Dr. Maria Claudia Costa  
Irigoyen**

Heart Institute (InCor),  
Hypertension Unit, University of  
Sao Paulo, Sao Paulo 05403-900,  
Brazil

**Prof. Dr. Kátia De Angelis**

Physiology Department, Federal  
University of Sao Paulo UNIFESP,  
São Paulo 04023-901, SP, Brazil

Deadline for manuscript  
submissions:

**closed (29 February 2024)**

### Message from the Guest Editors

Dear Colleagues,

The role of the autonomic nervous system in chronotropic, inotropic, dromotropic, and lusitropic aspects of cardiac function is known. Thus, it is unsurprising that autonomic dysfunction participates in the development and progression of major cardiovascular diseases, including hypertension, myocardial infarction, heart failure, and sudden cardiac death. In fact, evidence has shown that cardiovascular dysfunction associated with myocardial infarction and heart failure. Although these initial studies are promising, it is essential to advance our knowledge of the cardiovascular autonomic effects of both traditional and new pharmacological therapies, considering their possible pleiotropic effects or the remaining risk, for the development and implementation of precise neuromodulatory therapies. Therefore, this Special Issue is focused on the neuromodulatory effects of drugs and therapies in cardiovascular disease.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)